<DOC>
	<DOCNO>NCT01242111</DOCNO>
	<brief_summary>This multicenter , open-label extension study design ass long-term efficacy safety 2.0 milligram ( mg ) /kilogram ( kg ) /week BMN 110 patient diagnosed Mucopolysaccharidosis IVA ( MPS IVA ) . Patients MPS IVA , enrol prior BioMarin sponsor clinical study BMN 110 ( NCT00884949 ; Study Identification Number MOR-002 ) , eligible enroll study ( except patient enrolled NCT01275066 ; Study Identification Number MOR-004 ) .</brief_summary>
	<brief_title>A Study Evaluate Long-Term Efficacy Safety BMN 110 Patients With Mucopolysaccharidosis IVA ( Morquio A Syndrome )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis IV</mesh_term>
	<criteria>Willing able provide write , sign informed consent , case patient age 18 ( 16 year , depend region ) , provide write assent ( require ) write informed consent legally authorize representative nature study explain , prior researchrelated procedure . Sexually active patient must willing use acceptable method contraception participate study . Females childbearing potential must negative pregnancy test Baseline willing additional pregnancy test study . Must enrol prior BioMarin sponsor clinical study BMN 110 . Pregnant breastfeed Baseline planning become pregnant ( self partner ) time study . Use investigational product ( BMN 110 prior clinical study ) investigational medical device within 30 day prior Baseline , requirement investigational agent prior completion schedule study assessment . Concurrent disease condition , include limited symptomatic cervical spine instability , clinically significant spinal cord compression , severe cardiac disease would interfere study participation safety determine Investigator . Any condition , view Investigator , place patient high risk poor treatment compliance complete study . Were enrol MOR004 ( patient MOR004 may eligible participate separate , appropriately design , extension study ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Mucopolysaccharidosis IV type A</keyword>
	<keyword>MPS IV Type A</keyword>
	<keyword>Mucopolysaccharidosis IVA</keyword>
	<keyword>MPS IVA</keyword>
	<keyword>Morquio A Syndrome</keyword>
	<keyword>Lysosomal Storage Disorder</keyword>
	<keyword>LSD</keyword>
	<keyword>N-acetylgalactosamine-6-sulfatase</keyword>
	<keyword>N-acetylgalactosamine-6-sulfate sulfatase</keyword>
	<keyword>galactose-6-sulfatase</keyword>
	<keyword>GALNS</keyword>
	<keyword>enzyme replacement therapy</keyword>
	<keyword>ERT</keyword>
</DOC>